- Home
- EDSA vs BFRI Comparison
EDSA vs BFRI Comparison
Compare EDSA & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- BFRI
- Stock Information
- Founded
- EDSA 2015
- BFRI 1997
- Country
- EDSA Canada
- BFRI United States
- Employees
- EDSA N/A
- BFRI N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- BFRI Health Care
- Exchange
- EDSA Nasdaq
- BFRI Nasdaq
- Market Cap
- EDSA 6.2M
- BFRI 6.2M
- IPO Year
- EDSA N/A
- BFRI 2021
- Fundamental
- Price
- EDSA $1.70
- BFRI $1.10
- Analyst Decision
- EDSA Strong Buy
- BFRI Strong Buy
- Analyst Count
- EDSA 1
- BFRI 1
- Target Price
- EDSA $21.00
- BFRI $7.00
- AVG Volume (30 Days)
- EDSA 17.7K
- BFRI 960.5K
- Earning Date
- EDSA 02-07-2025
- BFRI 03-14-2025
- Dividend Yield
- EDSA N/A
- BFRI N/A
- EPS Growth
- EDSA N/A
- BFRI N/A
- EPS
- EDSA N/A
- BFRI N/A
- Revenue
- EDSA N/A
- BFRI $35,358,000.00
- Revenue This Year
- EDSA N/A
- BFRI $17.69
- Revenue Next Year
- EDSA N/A
- BFRI $19.71
- P/E Ratio
- EDSA N/A
- BFRI N/A
- Revenue Growth
- EDSA N/A
- BFRI 5.17
- 52 Week Low
- EDSA $1.55
- BFRI $0.61
- 52 Week High
- EDSA $5.99
- BFRI $2.43
- Technical
- Relative Strength Index (RSI)
- EDSA 40.80
- BFRI 53.42
- Support Level
- EDSA $1.56
- BFRI $0.97
- Resistance Level
- EDSA $1.97
- BFRI $1.11
- Average True Range (ATR)
- EDSA 0.15
- BFRI 0.16
- MACD
- EDSA 0.02
- BFRI -0.01
- Stochastic Oscillator
- EDSA 31.84
- BFRI 15.38
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.